Keyrelaks (Thiocolchicoside) is generally used as an adjunctive therapeutic agent to help manage symptoms related to painful and rigid muscle manifestations. The approved indication includes adjunctive treatment for acute muscle contractures in spinal pathology. It is considered relevant across clinical settings where symptoms are driven by increased muscular activity.

The agent is commonly applied in conditions characterized by periods of heightened symptoms, such as those associated with acute spinal pathology. This includes common presentations like acute lumbago, sciatica, and torticollis (wry neck). The medication addresses symptom clusters where excessive muscle tone (hypertonia) may contribute to movement restriction and functional strain. It is often used during rehabilitation phases following injury or to manage post-operative reflex contractures.

By helping to relax the rigid musculature, Keyrelaks supports symptomatic relief, which may assist patients with coping more steadily and contribute to improved comfort and functional stability. It is relevant when spasms interfere with daily comfort or become more disruptive, providing support that helps ease the overall symptom burden.

---

Quick Fact: Symptomatic support for Painful Muscle Contractures

The eligibility profile for systemic Keyrelaks (Thiocolchicoside) is highly restricted, defined by a specific set of contraindications and limitations mandated in official regulatory documents.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and Adolescents from 16 years of age and older only.
Populations for whom use is not recommended	Individuals requiring long-term treatment for chronic muscle conditions.
Populations for whom use is contraindicated	Patients with hypersensitivity to the substance or to colchicine.
Age-related eligibility rules	Contraindicated in children and adolescents under 16 years of age.
Pregnancy and lactation eligibility status	Contraindicated during pregnancy, lactation (breastfeeding), and in women of childbearing potential not using effective contraception.
Eligibility-related restrictions	Use is strictly limited to short-term treatment for acute episodes. Special caution is required for patients with epilepsy or a risk of convulsions.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): The official profile defines absolute prohibition (Contraindicated) for groups based on reproductive safety and age.

Regulatory basis: Restrictions and contraindications are based on a European Medicines Agency (EMA) referral following concerns over the genotoxic potential of a metabolite.

Eligibility-context constraints: Use is subject to a mandatory short-term restriction for all eligible users.

---

Official eligibility statements:

• Use is strictly allowed only in adults and adolescents from 16 years of age.
• Use is contraindicated in women who are pregnant, breastfeeding, or of childbearing potential not using effective contraception.
• Use is not recommended for the long-term treatment of chronic conditions.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine based on a strict set of absolute contraindications related to reproductive safety and minimum age, coupled with a fundamental constraint that limits the use of the drug to short-term treatment of acute episodes only.

Keyrelaks’ official interaction profile focuses predominantly on pharmacodynamic effects with other medicines that influence the central nervous system or smooth muscle tone. No drug-drug combination is formally listed as a contraindication in regulatory documents.

Interaction Scope	Official Regulatory Statement
Pharmacodynamic Interaction	Co-administration with other skeletal muscle relaxants is not recommended as these agents may increase one another's impact (additive effect).
Use with Caution	Caution is advised when used with other medicines affecting smooth muscles due to a possible increase in the incidence rate of side effects.
Co-administration Findings	Thiocolchicoside has been used successfully and safely in combination with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), analgesics, sedatives, and barbiturates in clinical experimentation.
Exposure/Toxicity Interaction	Serious cases of liver conditions (fulminant hepatitis) have been reported in patients taking NSAIDs or paracetamol concomitantly during post-market use.
Substance Interaction	Alcohol use may result in increased drowsiness or sedation due to an additive effect on the central nervous system.
Timing Requirements	No mandatory timing separation rules are documented in the regulatory text.
Population Note	The official labeling states that no study on interaction with special populations has been reported.

The regulatory framework defines this product’s interaction structure by classifying combinations based on the resulting practical risk, such as being "not recommended" or requiring "caution advised." The label notes that while the product is metabolized by the CYP system, no formal restrictions based on enzyme inhibitors or inducers are currently provided. Furthermore, the official labeling states that no specific study on interactions with special populations, such as those with hepatic or renal impairment, has been reported.

Keyrelaks acts through the engagement of specific molecular targets that influence signaling cascades associated with heightened physiological responses. The action results in systemic changes in pathway activity.

Receptor-Mediated Signaling Modulation

Keyrelaks acts within domains involving receptor-mediated signaling, specifically by influencing key receptors associated with pathway activity. This initiates or suppresses signaling sequences, modifying early molecular steps that influence systemic pathway activity. The effect results in a shift toward reduced pathway activity in targeted systems.

Enzyme-Based Pathway Adjustment

The compound is relevant in systems where targeted enzyme-based pathway adjustment is required. Keyrelaks engages mechanisms that influence processes by altering the activity of specific enzymes and mediators that drive pathway activity. This action alters feedback mechanisms to reduce the level of excessive mediator activity.

How Keyrelaks (Thiocolchicoside) is Used: Administration Guidelines

Keyrelaks, containing Thiocolchicoside, is a medicine whose systemic use (oral and injectable forms) is governed by guidelines focusing on short-term, acute applications. The following instructions define the proper usage according to established parameters for the medicine.

---

Approved Systemic Routes and Dosing

The medicine is approved for systemic administration via two main routes for adults and adolescents from 16 years of age.

Administration Route	Maximum Dose Per Administration	Maximum Daily Dose	Maximum Duration
Oral Use (Tablets/Capsules)	8 mg	16 mg (Twice daily)	7 consecutive days
Intramuscular (IM) Use (Injection)	4 mg	8 mg (Twice daily)	5 consecutive days

---

Use Constraints

Thiocolchicoside is intended only for short-term, adjunct treatment of painful muscle contractures. Established parameters stipulate that doses exceeding the maximum recommended limits and long-term use must be avoided. The systemic forms are not to be used in children and adolescents under 16 years of age.

Oral forms should be swallowed with a glass of water. In the event of diarrhoea, the dosage should be reduced. This protocol defines the medicine as a time-limited, dose-restricted therapeutic agent, ensuring its use adheres to the strict parameters for acute application.

Evidence for Acute Painful Muscle Contractures

The primary research base for Keyrelaks (Thiocolchicoside) consists mainly of short-term randomized controlled trials (RCTs). These studies were evaluated in adults with acute musculoskeletal symptoms, such as low back pain and sciatica. Research explored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Most trials was studied for use as an adjunct (an add-on) to other common treatments, such as non-steroidal anti-inflammatory drugs (NSAIDs), rather than as a standalone therapy. Findings describe data observed in the studies related to measurements taken during the short treatment period. However, meta-analyses often describe the collected evidence as heterogeneous, meaning the methods and results varied significantly. Overall evidence quality varies across studies, and certainty remains low to moderate.

---

Duration and Limitations of Research

The typical follow-up durations were limited across most pivotal studies, often just 5 to 7 days of treatment, with few data extending beyond 14 to 28 days. As a result, long-term effects are not fully established.

This lack of extended data contributes to regulatory restrictions on the duration of systemic use (oral or injection) for this medicine, confining its use to the acute, short-term setting. Data for certain groups remain insufficient, including older adults. Furthermore, non-clinical research data show patterns related to potential chromosomal changes with a specific metabolite, a finding that was factored into the strict dose and duration restrictions imposed by regulatory bodies.

Key Studies & References

1. Efficacy of Thiocolchicoside for Musculoskeletal Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
2. Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature
3. A multi-center, double-blind, randomized parallel-group Phase IV study comparing the efficacy and safety of thiocolchicoside ointment versus placebo in patients with chronic mechanical low back pain and an acute muscle spasm

Common questions about Keyrelaks (FAQ)

Q: Are there any specific foods or drinks I should avoid while using Keyrelaks?

According to the official product information, alcohol should be avoided while using Keyrelaks. Regulatory information describes that co-administration with alcohol has been associated with increased drowsiness or sedation due to an additive central nervous system effect. Official labeling does not list specific foods to avoid.

Q: Can older adults (seniors) use Keyrelaks?

Keyrelaks is officially approved for use in adults and adolescents aged 16 years and older. However, regulatory documents point out that data specifically for older adults remain insufficient. Use for all eligible patients is subject to the strict short-term treatment restrictions defined in the official guidelines.

Q: Can people with liver problems use Keyrelaks?

Pre-existing liver problems are not listed as a formal contraindication in the official labeling. However, serious cases of hepatitis (liver inflammation) have been reported in post-market experience, particularly when Keyrelaks was taken alongside certain other medications. The official documentation indicates that no specific studies on interactions or use in patients with liver impairment have been reported.

Q: How is Keyrelaks eliminated from the body?

The active substance in Keyrelaks, thiocolchicoside, is broken down by the body into several components. This process includes the breakdown of the medicine into components, which is a factor in the strict regulatory restrictions placed on the medicine's maximum dose and duration.

Q: Can Keyrelaks be taken by people with kidney disease?

Formal restrictions for people with kidney disease (renal impairment) are not detailed in the official documentation. Regulatory sources indicate that no specific study on interactions or use in special populations, such as those with kidney impairment, has been reported.

Q: How quickly should someone notice the effects of Keyrelaks after starting it?

Clinical studies supporting the use of Keyrelaks primarily measure the effects of the medicine during the short-term treatment period. Studies have examined outcomes related to reduced physical discomfort and improved daily functioning during the first week of therapy, reflecting the short-term use of the medicine.

Q: How long does Keyrelaks stay in the body after the last dose?

Pharmacokinetic studies, which describe how the body processes the medicine, show that the elimination half-life of the active substance, thiocolchicoside, is typically reported to be about 5 to 6 hours. The half-life represents the estimated time required for half of the substance to be removed from the body’s system.

Q: Is there a risk of becoming dependent on Keyrelaks?

The medicine is classified as a centrally-acting skeletal muscle relaxant, and regulatory documents do not list dependence as a known risk. The product information also notes that use of Keyrelaks is strictly limited to short-term treatment only.

Q: Is Keyrelaks taken with food, or on an empty stomach?

Official administration guidelines state that the medicine should be swallowed with a glass of water. Regulatory documents do not provide specific instructions stating that Keyrelaks must be taken strictly with food or on an empty stomach.

Q: Are there any restrictions on physical activity while taking Keyrelaks?

Official warnings state that Keyrelaks commonly causes drowsiness. Official labeling contains a warning that caution should be exercised when operating machinery or driving due to the risk of drowsiness, but no specific restrictions on general physical activity are documented.

Q: Is Keyrelaks effective for all stages of the condition it treats?

Regulatory documents explicitly indicate that systemic Keyrelaks is approved only as an adjunct treatment for acute painful muscle contractures. Its use is strictly limited to these short-term episodes and is not intended for the long-term or chronic management of a condition.

Q: What happens if a child accidentally takes Keyrelaks?

Systemic use of Keyrelaks is absolutely contraindicated in children and adolescents under 16 years of age due to safety concerns. The official labeling states that the medicine must be kept out of the reach of children to prevent accidental ingestion and the risk of serious harm.

Q: What are the official patient education resources for Keyrelaks?

Regulatory bodies and manufacturers distribute official patient education materials, such as a patient card or leaflet, as part of the risk management plan. These resources are designed to highlight the important safety warnings and restrictions associated with the medicine.

How to Store and Dispose of Keyrelaks?

The official labeling for Keyrelaks (Thiocolchicoside) defines strict conditions necessary to maintain drug stability and ensure safety.

Storage/Disposal Component	Regulatory Requirement
Storage Temperature	Store at room temperature, typically specifying not above 30 C.
Environmental Protection	Protect from light and moisture. Keep the container tightly closed in a dry and well-ventilated place.
Child Safety	Keep out of the reach of children. The product is often classified to be stored locked up or in an area accessible only to qualified persons.
Disposal Instructions	Dispose of unused product according to local regulations. Do not discard medicines into wastewater (drains) or household trash.

These mandates ensure the chemical stability of the medicine over its labeled shelf-life. Final disposal of unused or expired product must be managed through designated take-back programs or returned to a pharmacy to avoid environmental contamination.